| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:06 | Cannara Biotech Inc (2): Cannara Biotech to release fiscal 2026 results Nov. 30 | 5 | Stockwatch | ||
| Mo | Stocks in Play: Cannara Biotech Inc. | - | Baystreet.ca | ||
| 05.10. | Cannara Biotech Inc (2): Cannara expands Curaleaf supply deal to $34-million | 1 | Stockwatch | ||
| 05.10. | Curaleaf Holdings Inc (2): Cannara expands Curaleaf supply deal to $34-million | 10 | Stockwatch | ||
| 11.09. | Cannara Biotech Inc (2): Cannara increases credit facility to $80-million | 2 | Stockwatch | ||
| 01.09. | Cannara Biotech Inc (2): Cannara Biotech appoints Fozard CFO | 1 | Stockwatch | ||
| 01.09. | Nicholas Fozard wird neuer Finanzvorstand bei Cannara Biotech | 1 | Investing.com Deutsch | ||
| CANNARA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 01.09. | Cannara Biotech names Nicholas Fozard as chief financial officer | 2 | Investing.com | ||
| 13.08. | Cannara Biotech Inc (2): Cannara arranges automatic share purchase plan | 1 | Stockwatch | ||
| 22.07. | Cannara Biotech Inc (2): Cannara gets OK from TSX for NCIB | 1 | Stockwatch | ||
| 22.07. | Cannara Biotech Inc.: Cannara Announces Normal Course Issuer Bid | 2 | GlobeNewswire (USA) | ||
| 15.07. | Cannara Q3 2026 slides: revenue climbs 16% as cash flow drops | 2 | Investing.com | ||
| 15.07. | Cannara Biotech Reports Q3 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| 15.07. | Cannara Biotech Inc.: Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion | 433 | GlobeNewswire (Europe) | Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA1... ► Artikel lesen | |
| 15.07. | Cannara Biotech reports Q3 results | 3 | Seeking Alpha | ||
| 15.07. | Cannara Biotech Inc (2): Cannara Biotech, Curaleaf sign supply agreement | 2 | Stockwatch | ||
| 15.07. | Curaleaf Holdings Inc (2): Cannara Biotech, Curaleaf sign supply agreement | 2 | Stockwatch | ||
| 14.07. | Stocks in Play: Cannara Biotech Inc. | 1 | Baystreet.ca | ||
| 08.07. | Cannara Biotech Inc (2): Cannara Biotech to release Q3 results on July 15 | 1 | Stockwatch | ||
| 02.07. | Cannara Biotech Inc (2): Cannara obtains Canadian rights to Ampersand technology | 1 | Stockwatch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 36,975 | -2,14 % | BERENBERG stuft NOVO NORDISK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Novo Nordisk mit einem Kursziel von 305 dänischen Kronen auf "Hold" belassen. Das dritte Quartal sei solide verlaufen, schrieb... ► Artikel lesen | |
| AURORA CANNABIS | 4,080 | -2,06 % | Aurora Cannabis: Deal-Hürde fällt - was jetzt noch fehlt | ||
| CANOPY GROWTH | 0,488 | -1,99 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: STADA launches Virustad in Germany - based on Enzymatica's ColdZyme technology | STADA has launched the oral spray Virustad in the German pharmacy market. Virustad is built on Enzymatica's clinically documented ColdZyme® technology. The launch follows the partnership agreement signed... ► Artikel lesen | |
| TILRAY BRANDS | 2,125 | -0,70 % | Tilray Brands in downtrend: Bearish signals defy Wall Street's 'Buy' call | ||
| INNOCAN PHARMA | 1,070 | +7,43 % | InnoCan Pharma: Finanzierung und Vertriebsnews, aber die Aktie bleibt am Tief - was jetzt zählt | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| CRONOS GROUP | 2,906 | -2,42 % | Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter Results | Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis... ► Artikel lesen | |
| SYNBIOTIC | 0,136 | +38,79 % | SYNBIOTIC SE: Zuvor aufgezeigte Risiken haben sich materialisiert; Rating und Kursziel under review | SYNBIOTIC hat angekündigt, einen Insolvenzantrag zu stellen, nachdem es dem Unternehmen angesichts anhaltend schwieriger Marktbedingungen nicht gelungen ist, eine ausreichende Finanzierung sicherzustellen.... ► Artikel lesen | |
| DIGICANN VENTURES | 0,006 | 0,00 % | CSE Bulletin: Halted for Fundamental Change - Digicann Ventures Inc. (DCNN.X) | Le 6 novembre/November 2026
Trading in the shares of Digicann Ventures Inc. will remain halted pending receipt and review of acceptable documentation regarding the Fundamental Change pursuant to... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,635 | -3,64 % | Organigram Global Inc: Organigram has 180 days to cure Nasdaq non-compliance | ||
| GREEN THUMB INDUSTRIES | 5,450 | -1,62 % | Green Thumb Has $316 Million in Cash, and Same-Store Sales Are Growing Again. Is It the Smartest Pot Stock to Buy? | ||
| SNDL | 1,219 | -0,33 % | Immortal Dragons: Sundial Initiative Advisor Boyang Wang Sponsors Nakauchi Lab's Work on "Bodyoids" | SINGAPORE, SG / ACCESS Newswire / July 30, 2026 / Boyang Wang, advisor to the Sundial Initiative and founder and CEO of the longevity fund Immortal Dragons, has sponsored the Nakauchi Lab, led by stem... ► Artikel lesen | |
| CRESCO LABS | 0,414 | -7,07 % | Cresco Labs: Q3 Revenue Reaches $173 Million And Free Cash Flow Totals $21 Million | ||
| NOVERIS HEALTH SCIENCES | 0,025 | 0,00 % | Noveris Health Sciences Inc.: Noveris Health Sciences Announces Commencement of Strategic Review Process | Vancouver, British Columbia--(Newsfile Corp. - November 13, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces that its board of directors... ► Artikel lesen |